S'abonner

Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study - 23/12/21

Doi : 10.1016/S1473-3099(21)00090-6 
Christos Kokaliaris, MSc a, b, Amadou Garba, PhD c, Martin Matuska, MSc a, b, Rachel N Bronzan, MD d, Daniel G Colley, ProfPhD e, Ameyo M Dorkenoo, PhD f, Uwem F Ekpo, PhD g, Fiona M Fleming, PhD h, Michael D French, PhD i, Achille Kabore, MPH j, Jean B Mbonigaba, MPH k, Nicholas Midzi, ProfPhD l, Pauline N M Mwinzi, PhD m, n, Eliézer K N’Goran, ProfPhD o, p, Maria Rebollo Polo, PhD n, Moussa Sacko, PhD q, Louis-Albert Tchuem Tchuenté, ProfPhD r, s, Edridah M Tukahebwa, PhD t, Pitchouna A Uvon, PhD u, Guojing Yang, PhD a, b, Lisa Wiesner, MSc a, b, Yaobi Zhang, PhD v, Jürg Utzinger, ProfPhD a, b, Penelope Vounatsou, PhD a, b,
a Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland 
b University of Basel, Basel, Switzerland 
c Department of Control of Neglected Tropical Diseases, WHO, Geneva, Switzerland 
d Health & Development International, Newburyport, MA, USA 
e Schistosomiasis Consortium for Operational Research and Evaluation, Center for Tropical and Emerging Global Diseases, and Department of Microbiology, University of Georgia, Athens, GA, USA 
f Department of Parasitology and Mycology, University of Lomé, Lomé, Togo 
g Department of Pure and Applied Zoology, Federal University of Agriculture, Abeokuta, Nigeria 
h SCI Foundation, London, UK 
i RTI International, Washington DC, USA 
j FHI360, Washington DC, USA 
k Malaria and Other Parasitic Disease Division, Rwanda Biomedical Center, Ministry of Health, Kigali, Rwanda 
l Department of Medical Microbiology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe 
m Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya 
n Expanded Special Project for Elimination of Neglected Tropical Diseases, WHO, Regional Office for Africa, Brazzaville, Congo 
o Unité de Formation et de Recherche Biosciences, Université Félix Houphouët-Boigny, Abidjan, Côte d’Ivoire 
p Centre Suisse de Recherches Scientifiques en Côte d’Ivoire, Abidjan, Côte d’Ivoire 
q Department of Diagnostic and Biomedical Research, Institut National de Recherche en Santé Publique, Bamako, Mali 
r Laboratory of Parasitology and Ecology, Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon 
s Centre for Schistosomiasis and Parasitology, Yaoundé, Cameroon 
t Vector Control Division, Ministry of Health, Kampala, Uganda 
u Neglected Tropical Diseases Unit, Ministère de la Santé Publique, Kinshasa, Democratic Republic of the Congo 
v Regional Office for Africa, Helen Keller International, Dakar, Senegal 

* Correspondence to: Dr Penelope Vounatsou, Swiss Tropical and Public Health Institute, CH-4002 Basel, Switzerland Swiss Tropical and Public Health Institute Basel CH-4002 Switzerland

Summary

Background

Over the past 20 years, schistosomiasis control has been scaled up. Preventive chemotherapy with praziquantel is the main intervention. We aimed to assess the effect of preventive chemotherapy on schistosomiasis prevalence in sub-Saharan Africa, comparing 2000–10 with 2011–14 and 2015–19.

Methods

In this spatiotemporal modelling study, we analysed survey data from school-aged children (aged 5–14 years) in 44 countries across sub-Saharan Africa. The data were extracted from the Global Neglected Tropical Diseases database and augmented by 2018 and 2019 survey data obtained from disease control programmes. Bayesian geostatistical models were fitted to Schistosoma haematobium and Schistosoma mansoni survey data. The models included data on climatic predictors obtained from satellites and other open-source environmental databases and socioeconomic predictors obtained from various household surveys. Temporal changes in Schistosoma species prevalence were estimated by a categorical variable with values corresponding to the three time periods (2000–10, 2011–14, and 2015–19) during which preventive chemotherapy interventions were scaled up.

Findings

We identified 781 references with relevant geolocated schistosomiasis survey data for 2000–19. There were 19 166 unique survey locations for S haematobium and 23 861 for S mansoni, of which 77% (14 757 locations for S haematobium and 18 372 locations for S mansoni) corresponded to 2011–19. Schistosomiasis prevalence among school-aged children in sub-Saharan Africa decreased from 23·0% (95% Bayesian credible interval 22·1–24·1) in 2000–10 to 9·6% (9·1–10·2) in 2015–19, an overall reduction of 58·3%. The reduction of S haematobium was 67·9% (64·6–71·1) and that of S mansoni 53·6% (45·2–58·3) when comparing 2000–10 with 2015–19.

Interpretation

Our model-based estimates suggest that schistosomiasis prevalence in sub-Saharan Africa has decreased considerably, most likely explained by the scale-up of preventive chemotherapy. There is a need to consolidate gains in the control of schistosomiasis by means of preventive chemotherapy, coupled with other interventions to interrupt disease transmission.

Funding

European Research Council and WHO.

Le texte complet de cet article est disponible en PDF.

Plan


© 2022  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 22 - N° 1

P. 136-149 - janvier 2022 Retour au numéro
Article précédent Article précédent
  • Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d’Ivoire, Laos, and Pemba Island, Tanzania: a double-blind, parallel-group, phase 3, randomised controlled trial
  • Eveline Hürlimann, Ladina Keller, Chandni Patel, Sophie Welsche, Jan Hattendorf, Said M Ali, Shaali M Ame, Somphou Sayasone, Jean T Coulibaly, Jennifer Keiser
| Article suivant Article suivant
  • 100 years of Mycobacterium bovis bacille Calmette-Guérin
  • Christoph Lange, Peter Aaby, Marcel A Behr, Peter R Donald, Stefan H E Kaufmann, Mihai G Netea, Anna M Mandalakas

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.